| Standard Type | Activity Comment |
|---|---|
| Activity | Active |
| Activity | Active |
| Activity | Active |
| Activity | Active |
| Activity | Active |
| Activity | Active |
| Activity | Active |
| Activity | Active |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| mortality | = | 46.7 | % |
| mortality | = | 14.4 | % |
| mortality | = | 27.8 | % |
| mortality | = | 10 | % |
| mortality | = | 18.9 | % |
| mortality | = | 18.9 | % |
| mortality | = | 6.7 | % |
| mortality | = | 43.3 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| mortality | = | 24.4 | % |
| mortality | = | 16.7 | % |
| mortality | = | 17.8 | % |
| mortality | = | 14.4 | % |
| mortality | = | 13.3 | % |
| mortality | = | 12.2 | % |
| mortality | = | 13.3 | % |
| mortality | = | 13.3 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| mortality | = | 28.9 | % |
| mortality | = | 68.9 | % |
| mortality | = | 54.4 | % |
| mortality | = | 75.6 | % |
| mortality | = | 67.8 | % |
| mortality | = | 68.9 | % |
| mortality | = | 80 | % |
| mortality | = | 43.3 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| LC90 | = | 7.97 | mg/ml |
| LC50 | = | 2460 | ug.mL-1 |
| LC90 | = | 2.26 | mg/ml |
| LC50 | = | 1400 | ug.mL-1 |
| LC90 | = | 3.24 | mg/ml |
| LC50 | = | 1410 | ug.mL-1 |
| LC90 | = | 3.2 | mg/ml |
| LC50 | = | 1060 | ug.mL-1 |
| LC90 | = | 2.13 | mg/ml |
| LC50 | = | 880 | ug.mL-1 |
| LC90 | = | 2.34 | mg/ml |
| LC50 | = | 1140 | ug.mL-1 |
| LC90 | = | 2.18 | mg/ml |
| LC50 | = | 710 | ug.mL-1 |
| LC90 | = | 7.33 | mg/ml |
| LC50 | = | 2690 | ug.mL-1 |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| mortality | = | 0 | % |
| mortality | = | 7.4 | % |
| mortality | = | 4.6 | % |
| mortality | = | 6 | % |
| mortality | = | 8.4 | % |
| mortality | = | 0 | % |
| mortality | = | 9.7 | % |
| mortality | = | 0 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| mortality | = | 100 | % |
| mortality | = | 0 | % |
| mortality | = | 12.4 | % |
| mortality | = | 7.5 | % |
| mortality | = | 20.5 | % |
| mortality | = | 22.4 | % |
| mortality | = | 10 | % |
| mortality | = | 29.9 | % |
| mortality | = | 11.9 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| mortality | = | 6 | % |
| mortality | = | 30.5 | % |
| mortality | = | 19.8 | % |
| mortality | = | 42.7 | % |
| mortality | = | 51.2 | % |
| mortality | = | 36.4 | % |
| mortality | = | 59.2 | % |
| mortality | = | 17.3 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| mortality | = | 32.6 | % |
| mortality | = | 76.3 | % |
| mortality | = | 49.5 | % |
| mortality | = | 72 | % |
| mortality | = | 83.8 | % |
| mortality | = | 71.7 | % |
| mortality | = | 83.8 | % |
| mortality | = | 32.1 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| mortality | = | 66.6 | % |
| mortality | = | 97.2 | % |
| mortality | = | 87.5 | % |
| mortality | = | 83.3 | % |
| mortality | = | 95.8 | % |
| mortality | = | 95.9 | % |
| mortality | = | 95.9 | % |
| mortality | = | 41.6 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| mortality | = | 72.2 | % |
| mortality | = | 98.7 | % |
| mortality | = | 97.2 | % |
| mortality | = | 98.7 | % |
| mortality | = | 98.7 | % |
| mortality | = | 96.5 | % |
| mortality | = | 97.7 | % |
| mortality | = | 82.2 | % |
| Species | Strain | IsPseudotypeVirus | AssayMeth | CellType | CellType2 | Target | Mutations | EC50Mod | EC50 | EC50Unit | ECOtherPct | ECOtherPctUnit | ECOtherConc | ECOtherConcUnit | ToxAssayMeth | ToxCellType | CC50Mod | CC50 | CC50Unit | TIMod | TI | RelResFoldChg | Comments | Reference | Citation | Other Information |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HIV-1 | LAI | RT | HuT TK+ | HuT 78 | Reverse transcriptase | < | 1 | uM | 100 | % | 1 | uM | MTT | > | 10 | uM | > | 10 | HuT TK+=HuT 78 CELLS EXPRESSING HSV-1 THYMIDINE KINASE; MEASUREMENT WAS MADE ON DAY10 POSTINFECTION AT 10 TCID50 | 9281520 | USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405. | |||||
| HIV-1 | MN | RT | HuT TK+ | HuT 78 | Reverse transcriptase | < | 0.3 | uM | 76.74 | % | 0.3 | uM | MTT | > | 10 | uM | > | 33.3 | HuT TK+=HuT 78 CELLS EXPRESSING HSV-1 THYMIDINE KINASE; MEASUREMENT WAS MADE ON DAY14 POSTINFECTION AT 10 TCID50 | 9281520 | USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405. | |||||
| HIV-1 | MN | RT | HuT TK+ | HuT 78 | Reverse transcriptase | < | 0.3 | uM | 69 | % | 0.3 | uM | MTT | > | 10 | uM | > | 33.3 | HuT TK+=HuT 78 CELLS EXPRESSING HSV-1 THYMIDINE KINASE; MEASUREMENT WAS MADE ON DAY14 POSTINFECTION AT 100 TCID50 | 9281520 | USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405. | |||||
| R5; CLINICAL ISOLATE | 1(JSL) | P24 | PBMC | Reverse transcriptase | MDR | 0.07 | uM | 90 | % | 1 | uM | MTT | > | 100 | uM | > | 1428 | HIV-1(JSL) WAS ISOLATED FROM PATIENTS WHO RECEIVED ANTIRETROVIRAL THERAPY FOR A LONG PERIOD AND WHOSE VIRUS ACQUIRED A NUMBER OF MUTATIONS IN THE RT- AND PR-ENCODING GENES; DETAILS OF MUTATIONS NOT GIVEN | 15280474 | SPIRODIKETOPIPERAZINE-BASED CCR5 INHIBITOR WHICH PRESERVES CC-CHEMOKINE/CCR5 INTERACTIONS AND EXERTS POTENT ACTIVITY AGAINST R5 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN VITRO. Journal of Virology 2004, 78(16), 8654-8662. | ECOtherConcMod:> | |||||
| HIV-1 | NL4-3 | LUCIFERASE | 1G5 T | Reverse transcriptase | < | 1 | uM | 99 | % | 1 | uM | TRYPAN BLUE | > | 1 | uM | > | 1 | ASSAY WAS CONDUCTED ON DAY 3 POST-INFECTION | 16725040 | INHIBITION OF HIGHLY PRODUCTIVE HIV-1 INFECTION IN T CELLS, PRIMARY HUMAN MACROPHAGES, MICROGLIA, AND ASTROCYTES BY SARGASSUM FUSIFORME. AIDS Research and Therapy 2006, 3(1), 15 PP. | CCOtherPct:6 | CCOtherPctUnit:% | CCOtherConc:1 | CCOtherConcUnit:uM | |||||
| HIV-1 | NL4-3 | LUCIFERASE | 1G5 T | Reverse transcriptase | < | 1 | uM | 99 | % | 1 | uM | TRYPAN BLUE | > | 1 | uM | > | 1 | ASSAY WAS CONDUCTED ON DAY 5 POST-INFECTION | 16725040 | INHIBITION OF HIGHLY PRODUCTIVE HIV-1 INFECTION IN T CELLS, PRIMARY HUMAN MACROPHAGES, MICROGLIA, AND ASTROCYTES BY SARGASSUM FUSIFORME. AIDS Research and Therapy 2006, 3(1), 15 PP. | CCOtherPct:7 | CCOtherPctUnit:% | CCOtherConc:1 | CCOtherConcUnit:uM | |||||
| HIV-1 | NL4-3 | LUCIFERASE | 1G5 T | Reverse transcriptase | < | 1 | uM | 99 | % | 1 | uM | TRYPAN BLUE | > | 1 | uM | > | 1 | ASSAY WAS CONDUCTED ON DAY 7 POST-INFECTION | 16725040 | INHIBITION OF HIGHLY PRODUCTIVE HIV-1 INFECTION IN T CELLS, PRIMARY HUMAN MACROPHAGES, MICROGLIA, AND ASTROCYTES BY SARGASSUM FUSIFORME. AIDS Research and Therapy 2006, 3(1), 15 PP. | CCOtherPct:3 | CCOtherPctUnit:% | CCOtherConc:1 | CCOtherConcUnit:uM | |||||
| HIV-1 | LAV | RT | U1(THF-.alpha. STIM) | U1 | Tumor necrosis factor alpha | ~ | 30 | ug/mL | 70 | % | 50 | ug/mL | > | 50 | ug/mL | > | 1.66 | CHRONICALLY HIV-1 INFECTED PROMONOCYTE CELL LINE | 8327469 | THALIDOMIDE INHIBITS THE REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1. Proceedings of the National Academy of Sciences of the United States of America 1993, 90, 5974-5978. | CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:50 | CCOtherConcUnit:ug/mL | |||||
| HIV-1 | BaL | P24 (DAY 18) | MACROPHAGES(GM-CSF) | Macrophage | Ribonucleotide reductase | < | 10 | uM | 75 | % | 10 | uM | > | 1000 | uM | > | 10 | MAXIMAL P24 EXPRESSION AT DAY 18 | 7973634 | HYDROXYUREA AS AN INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1 REPLICATION. Science 1994, 266(5186), 801-805. | CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:1000 | CCOtherConcUnit:uM | |||||
| HIV-1 | BaL | P24 (DAY 18) | MACROPHAGES(GM-CSF) | Macrophage | Ribonucleotide reductase | < | 10 | uM | 38 | % | 2 | uM | > | 1000 | uM | > | 10 | MAXIMAL P24 EXPRESSION AT DAY 18 | 7973634 | HYDROXYUREA AS AN INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1 REPLICATION. Science 1994, 266(5186), 801-805. | CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:1000 | CCOtherConcUnit:uM | |||||
| HIV-1 | BaL | P24 (DAY 18) | MACROPHAGES(GM-CSF) | Macrophage | Ribonucleotide reductase | < | 10 | uM | 99 | % | 50 | uM | > | 1000 | uM | > | 10 | MAXIMAL P24 EXPRESSION AT DAY 18 | 7973634 | HYDROXYUREA AS AN INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1 REPLICATION. Science 1994, 266(5186), 801-805. | ECOtherPctMod:> | CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:1000 | CCOtherConcUnit:uM | |||||
| HIV-1 | IIIB | RT | HT4(R116; AZT RESISTANT CELLS) | HT4 | Reverse transcriptase | ~ | 0.01 | uM | 70 | % | 0.01 | uM | ~` | 1 | uM | ~ | 100 | FLOXURIDINE APPEARS TO POTENTIATE AZT ACTIVITY AND ALSO HAVE SOME ANTI-HIV ACTIVITY IN AZT RESISTANT CELL LINES | 8827211 | USE OF FLOXURIDINE TO MODULATE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. AIDS Research and Human Retroviruses 1996, 12(11), 965-968. | ECOtherPctMod:~ | CCOtherPct:35 | CCOtherPctUnit:% | CCOtherConc:.1 | CCOtherConcUnit:uM | |||||
| HIV-1 | 1 | .beta.GAL AS A MEASURE OF TAT-MEDIATED TRANSACTIVATION | HeLa H12(HIV-1 LTR-Laz, TAT) | HeLa | Tat:TAR/LTR | < | 0.1 | uM | 52 | % | 0.1 | uM | TRYPAN BLUE | > | 100 | uM | > | 1000 | DRUG AND RECOMBINANT TAT WERE INTRODUCED INTO CELLS THROUGH ELECTROPORATION | 9561563 | CURCUMIN AND CURCUMIN DERIVATIVES INHIBIT TAT-MEDIATED TRANSACTIVATION OF TYPE 1 HUMAN IMMUNODEFICIENCY VIRUS LONG TERMINAL REPEAT. Research in Virology 1998, 149(1), 43-52. | |||||
| HIV-1 | 1 | .beta.GAL AS A MEASURE OF TAT-MEDIATED TRANSACTIVATION | HeLa H12(HIV-1 LTR-Laz, TAT) | HeLa | Tat:TAR/LTR | < | 0.01 | uM | 78 | % | 0.01 | uM | TRYPAN BLUE | > | 100 | uM | > | 10000 | DRUG AND RECOMBINANT TAT WERE INTRODUCED INTO CELLS THROUGH ELECTROPORATION | 9561563 | CURCUMIN AND CURCUMIN DERIVATIVES INHIBIT TAT-MEDIATED TRANSACTIVATION OF TYPE 1 HUMAN IMMUNODEFICIENCY VIRUS LONG TERMINAL REPEAT. Research in Virology 1998, 149(1), 43-52. | |||||
| HIV-1 | IIIB | SYNCYT FORM | MOLT-4/H9(HIV-1(IIIB)) | MOLT-4 | gp120 | < | 1 | uM | 95 | % | 10 | uM | -100 | 10 | uM | > | 10 | CHRONICALLY INFECTED H9 CELLS | 9343823 | TRIAZINE DYES INHIBIT HIV-1 ENTRY BY BINDING TO ENVELOPE GLYCOPROTEINS. Microbiology and Immunology 1997, 41(9), 717-724. | CCOtherPct:30 | CCOtherPctUnit:% | CCOtherConc:10 | CCOtherConcUnit:uM | |||||
| HIV-1 | 1 | .beta.GAL AS A MEASURE OF TAT-MEDIATED TRANSACTIVATION | HeLa H12(HIV-1 LTR-Laz, TAT) | HeLa | Tat:TAR/LTR | < | 0.01 | uM | 75 | % | 0.01 | uM | TRYPAN BLUE | > | 100 | uM | > | 10000 | DRUG AND RECOMBINANT TAT WERE INTRODUCED INTO CELLS THROUGH ELECTROPORATION | 9561563 | CURCUMIN AND CURCUMIN DERIVATIVES INHIBIT TAT-MEDIATED TRANSACTIVATION OF TYPE 1 HUMAN IMMUNODEFICIENCY VIRUS LONG TERMINAL REPEAT. Research in Virology 1998, 149(1), 43-52. | |||||
| HIV-1 | 1 | P24 | MT-4 | Integrase | < | 0.25 | uM | 95 | % | 0.25 | uM | MICROSCOPIC EXAMINATION | > | 20 | uM | > | 80 | IN THE PRESENCE OF 50% NHS | 16554152 | A SERIES OF 5-AMINOSUBSTITUTED 4-FLUOROBENZYL-8-HYDROXY-[1,6]NAPHTHYRIDINE-7-CARBOXAMIDE HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2006, 16(11), 2900-2904. | ECOtherPctMod:> | |||||
| HIV-1 | 1 | P24 | MT-4 | Integrase | < | 0.103 | uM | 95 | % | 0.103 | uM | MICROSCOPIC EXAMINATION | > | 20 | uM | > | 194 | IN THE PRESENCE OF 10% FBS | 16554152 | A SERIES OF 5-AMINOSUBSTITUTED 4-FLUOROBENZYL-8-HYDROXY-[1,6]NAPHTHYRIDINE-7-CARBOXAMIDE HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2006, 16(11), 2900-2904. | ECOtherPctMod:> | |||||
| HIV-1 | NL4-3 | RT | MT-4 | Reverse transcriptase | < | 1 | uM | 100 | % | 1 | uM | WST-8 | > | 1 | uM | > | 1 | MEASUREMENTS WERE MADE ON DAY 4, 6 AND 8 POST INFECTION | 15371436 | POLYARGININE INHIBITS GP160 PROCESSING BY FURIN AND SUPPRESSES PRODUCTIVE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTION. The Journal of Biological Chemistry 2004, 279(47), 49055-49063. | ||||||
| HIV-1 | LAI | RT | HuT 78 | Reverse transcriptase | < | 1 | uM | 57.14 | % | 1 | uM | MTT | > | 10 | uM | > | 10 | MEASUREMENT WAS MADE ON DAY10 POSTINFECTION AT 10 TCID50 | 9281520 | USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405. |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| mortality | = | 87.2 | % |
| mortality | = | 100 | % |
| mortality | = | 97.7 | % |
| mortality | = | 100 | % |
| mortality | = | 100 | % |
| mortality | = | 98.8 | % |
| mortality | = | 98.8 | % |
| mortality | = | 87.2 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| mortality | = | 100 | % |
| mortality | = | 100 | % |
| mortality | = | 100 | % |
| mortality | = | 100 | % |
| mortality | = | 100 | % |
| mortality | = | 100 | % |
| mortality | = | 100 | % |
| mortality | = | 100 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment |
|---|---|---|---|---|
| Repellency | = | 60 | % | |
| Activity | Not Active | |||
| Repellency | = | 80 | % |
| Standard Type | Activity Comment |
|---|---|
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| Activity | Not Active |
| EXPID | PREFIX | CONCENTRATION_UNIT | CONCENTRATION | PANELNBR | CELLNBR | PANELNAME | CELLNAME | PANELCODE | M_GIPRCNT | N_GIPRCNT | STDDEV_GIPRCNT | EXP_COUNT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2106OS49 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 88.231 | 1 | 0 | 1 |
| 2106OS49 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 87.1119 | 1 | 0 | 1 |
| 2106OS49 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 14.4371 | 1 | 0 | 1 |
| 2106OS49 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 89.7113 | 1 | 0 | 1 |
| 2106OS49 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 97.2463 | 1 | 0 | 1 |
| 2106OS49 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 90.0129 | 1 | 0 | 1 |
| 2106OS49 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 85.7031 | 1 | 0 | 1 |
| 2106OS49 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 30.8539 | 1 | 0 | 1 |
| 2106OS49 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 14.2896 | 1 | 0 | 1 |
| 2106OS49 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 85.8526 | 1 | 0 | 1 |
| 2106OS49 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 83.1036 | 1 | 0 | 1 |
| 2106OS49 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 84.2194 | 1 | 0 | 1 |
| 2106OS49 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 89.3237 | 1 | 0 | 1 |
| 2106OS49 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 85.6034 | 1 | 0 | 1 |
| 2106OS49 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 89.6643 | 1 | 0 | 1 |
| 2106OS52 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 91.2503 | 1 | 0 | 1 |
| 2106OS52 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 94.8714 | 1 | 0 | 1 |
| 2106OS52 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 93.7372 | 1 | 0 | 1 |
| 2106OS52 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 112.6132 | 1 | 0 | 1 |
| 2106OS52 | S | M | 1.0E-5 | 5 | 1 | Breast Cancer | MCF7 | BRE | 73.375 | 1 | 0 | 1 |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| mortality | = | 45 | % |
| mortality | = | 45 | % |
| mortality | = | 45 | % |
| mortality | = | 45 | % |
| mortality | = | 45 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment |
|---|---|---|---|---|
| mortality | Not Active | |||
| mortality | Not Active | |||
| mortality | Not Active | |||
| mortality | = | 75 | % | |
| mortality | Not Active |
| EXPID | PREFIX | CONCENTRATION_UNIT | CONCENTRATION | PANELNBR | CELLNBR | PANELNAME | CELLNAME | PANELCODE | M_GIPRCNT | N_GIPRCNT | STDDEV_GIPRCNT | EXP_COUNT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0809OS51 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 89.6274 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 94.0185 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 77.1805 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 76.1686 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 82.5618 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 88.7561 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 83.5845 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 92.7497 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 70.9555 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 58.7306 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 72.6041 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 90.3839 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 110.2345 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 97.6538 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 93.7697 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 56.4618 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 80.8893 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 79.078 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | -20.3008 | 1 | 0 | 1 |
| 0810OS71 | S | M | 1.0E-5 | 6 | 10 | Ovarian Cancer | IGROV1 | OVA | 72.0949 | 1 | 0 | 1 |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| LC90 | = | 0.32 | mg |
| LC50 | = | 0.14 | mg |
| LC90 | = | 0.3 | mg |
| LC50 | = | 0.2 | mg |
| LC90 | = | 0.16 | mg |
| LC50 | = | 0.1 | mg |
| LC90 | = | 0.28 | mg |
| LC50 | = | 0.2 | mg |
| LC90 | = | 0.46 | mg |
| LC50 | = | 0.2 | mg |
| Standard Type | Activity Comment |
|---|---|
| mortality | Not Active |
| mortality | Not Active |
| mortality | Not Active |
| mortality | Not Active |
| mortality | Not Active |